|
American College of Medical Genetics and Genomics br>
Policy Statements
|
ACTIVE LIST
|
|
|
|
|
|
| Title |
|
Copyright |
|
Publication |
|
| Alzheimer Disease |
|
|
|
|
|
Consensus Statement on Use of Apolipoprotein E Testing for Alzheimer Disease
|
|
1995, AMA |
|
1995 JAMA
274:1627-1629 |
|
|
Breast Cancer
|
| xxx |
Statement on Population Screening for BRCA-1 Mutation in Ashkenazi Jewish Women |
|
1996, ACMG |
|
1996 ACMG
Newsletter 7:9 |
|
| Conflict of Interest |
|
|
|
|
|
Conflict of Interest |
|
2009, ACMG |
|
e-publicaton |
|
| Cystic Fibrosis |
|
|
|
|
|
Laboratory Standards and Guidelines for Population Based Cystic Fibrosis Carrier Screening
|
|
2001, ACMG |
|
2001 Genet Med 3:2:149-154 |
|
|
Down Syndrome
|
|
|
|
|
|
Statement on Nutritional Supplements & Piracetam for Children with Down Syndrome
|
|
1996, ACMG |
|
1996 ACMG
Newsletter 6:12 |
|
| Emergency Preparedness (Report) |
|
|
|
|
|
Emergency preparedness for newborn screening and genetic services |
|
2009, ACMG |
|
2009 Genet Med
11:6:455-464 |
|
| FISH |
|
|
|
|
|
FISH2: FISH Technical and Clinical Assessment of: An ACMG/ASHG Position Statement. I: Technical Considerations
|
|
2000, ACMG |
|
2000 Genet Med
2:6:356-361 |
|
| Folic Acid |
|
|
|
|
|
Folic Acid and Neural Tube Defects
|
|
2010, ACMG |
|
2010 Genet Med
13:6:593-596 |
|
| Genetic Discrimination |
|
|
|
|
|
Points to Consider in Preventing Unfair Discrimination Based on Genetic Disease Risk: A Position Statement of the American College of Medical Genetics and Genomics
|
|
2001, ACMG
Reaffirmed 2005 |
|
2001 Genet Med
3:6: 436-437 |
|
| Genetic Testing |
|
|
|
|
|
Risk categorization for oversight of laboratory-developed tests for inherited conditions
|
|
2013, ACMG |
|
2013 published before print |
|
ACMG 2008 Policy Statement on Direct-to-Consumer Genetic Testing
|
|
2008, ACMG |
|
e-publication |
|
Genetic Testing in Adoption (ACMG/ASHG)
|
|
2000, ASHG |
|
2000 Am J Hum Genet 66:761-767 |
|
| Genomic Sequencing |
|
|
|
|
| |
Points to Consider in the Clinical Application of Genomic Sequencing |
|
2012, ACMG |
|
e-publication |
|
Legal & Ethical Issues
|
|
|
|
|
|
Duty to Re-Contact
|
|
1999, ACMG |
|
1999 Genet Med
1:174-172 |
|
Guidelines for Expert Witness Testimony for the Specialty of Medical Genetics
|
|
2000, ACMG |
|
2000 Genet Med
2:6:367-368 |
|
Position Statement on Gene Patents & Accessibility of Gene Testing |
|
1999, ACMG
Reaffirmed 2005
|
|
1999 Genet Med
1:237 |
|
Statement on Storage & Use of Genetic Materials
|
|
1995, ASHG |
|
1995 Am J Hum Genet 57: 1499-5000 |
|
| Managed Care |
|
|
|
|
|
Genetics and Managed Care
|
|
2001, ACMG
Reaffirmed 2005
|
|
2001 Genet Med
3:6:430-433 |
|
| Microarrays |
|
|
|
|
| |
American College of Medical Genetics and Genomics
recommendations for the design and performance
expectations for clinical genomic copy number
microarrays intended for use in the postnatal setting
for detection of constitutional abnormalities |
|
2010, ACMG |
|
2010 Genet Med
13:6:676-679 |
|
| Newborn Screening |
|
|
|
|
|
Position Statement on Importance of Residual Newborn Screening Dried Blood Spots |
|
2009, ACMG
|
|
e-publication |
|
Statement on Universal Newborn Hearing Screening
|
|
2000, ACMG
Reaffirmed 2005
|
|
2000 Genet Med
2:149-150 |
|
Tandem Mass Spectrometry in Newborn Screening
|
|
2000, ACMG
|
|
2000 Genet Med
2:267-269 |
|
Newborn Screening: Toward a Uniform Screening Panel and System
|
|
2006, ACMG |
|
2006 Genet Med
8:5:Supplement |
|
| Pharmacogenetics |
|
A Rapid ACCE1 Review of CYP2C9 and VKORC1 Allele Testing to Inform Warfarin Dosing in Adults at Elevated Risk for Thrombotic Events to Avoid Serious Bleeding
Click here to go to ACMG's comprehensive report on genetic testing and Warfarin dosing
|
|
2008, AMCG |
|
2008, Genet Med 10:89-98 |
|
Pharmacogenetic testing of CYP2C9 and VKORC1alleles for warfarin |
|
2008, ACMG |
|
2008, Genet Med 10:139-150 |
|
| Scope of Practice |
|
|
|
|
|
Medical Genetics Scope of Practice |
|
2008, ACMG |
|
e-publication |
|
|
|
|
|
|
|
RETIRED POLICY STATEMENTS
If you require copies of these retired documents, please contact ACMG at acmg@acmg.net
|
|
| Title |
|
Copyright |
|
Date Retired |
|
|
Carrier Testing for Canavan Disease
|
|
1998, ACMG
|
|
Retired 11/21/10 |
|
|
Direct-to-Consumer Genetic Testing |
|
2004, ACMG
|
|
Retired 04/07/08
|
|
|
FISH1: Policy Statement on Prenatal Interphase |
|
1993, ASHG
|
|
Retired 1/20/01 |
|
Folic Acid & Pregnancy |
|
1994, ACMG |
|
Retired 10/26/04
|
|
Folic Acid: Statement on Fortification & Supplementation |
|
1997, ACMG |
|
Retired 10/26/04
|
|
Policy Statement on Diagnostic and Carrier Testing for Fragile X Syndrome |
|
1994,
Wiley-Liss |
|
Reitred 11/03/05
|
|
Statement on Multiple Marker Screening in Pregnant Women: See Second Trimester Maternal Serum Screening for Fetal Open Neural Tube Defects and Aneuploidy
|
|
1996, ACMG |
|
Retired 9/22/04 |
|
Position Statement on Multiple Marker Screening in Women 35 and Older: See Second Trimester Maternal Serum Screening for Fetal Open Neural Tube Defects and Aneuploidy
|
|
1994, ACMG |
|
Retired 9/22/04 |
